National Cancer Institute (NCI): all 3,554 studies

Page 4 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant ChemotherapyNot yet recruitingNCT01595074
• Clinical and Genetic Studies of Li-Fraumeni SyndromeRecruitingNCT01443468
• Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisRecruitingNCT01441089
• Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingNCT01419561Phase 2
• Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal CancerRecruitingNCT01313442
• DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyRecruitingNCT01247597
• Apheresis of Patients With ImmunodeficiencyRecruitingNCT01212055
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
• Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological StudiesRecruitingNCT01109394
• Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentRecruitingNCT01087333
• Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsRecruitingNCT01005654
• Biology Studies of Hematologic CancersEnrolling by invitationNCT00923442
• Collection of Blood From Patients With Prostate CancerRecruitingNCT00923221
• Data Collection, Clinical Care and Interventions in CCR, NCIEnrolling by invitationNCT00923065
• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by invitationNCT00923026
• Collection of Tissue Samples for Cancer ResearchRecruitingNCT00900198
• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruitingNCT00451022
• Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-FrederickEnrolling by invitationNCT00339911
• Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung LiningRecruitingNCT00242723
• Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host DiseaseRecruitingNCT00092235
• Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma MultiformeRecruitingNCT00083512
• Harvesting Cells for Experimental Cancer TreatmentsEnrolling by invitationNCT00068003
• Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal CancerRecruitingNCT00050752
• Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaRecruitingNCT00040352
• Collection of Blood From Patients With CancerRecruitingNCT00034216
• Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney CancerRecruitingNCT00033137
• Collection of Blood and Urine From Patients Undergoing Radiation TherapyEnrolling by invitationNCT00027326
• Cancer in Inherited Bone Marrow Failure SyndromesRecruitingNCT00027274
• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseRecruitingNCT00026884
• Evaluation of Late Effects and Natural History of Disease in Patients Treated With RadiotherapyRecruitingNCT00026650
• Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerRecruitingNCT00006518
• Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruitingNCT00001823
• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruitingNCT00001238
• Psychological Benefits of a Normalized Camping Experience for Children With CancerRecruitingNCT00001186
• Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical CarcinomasTerminatedNCT06865677Phase 2Results posted
• Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)Active, not recruitingNCT06400251Phase 2Results posted
• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)Active, not recruitingNCT06400238Phase 2Results posted
• Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)Active, not recruitingNCT06390852Phase 2Results posted
• Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)Active, not recruitingNCT06390839Phase 2Results posted
• Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)Active, not recruitingNCT06390826Phase 2Results posted
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)Active, not recruitingNCT06385483Phase 2Results posted
• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)Active, not recruitingNCT06360588Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)Active, not recruitingNCT06360575Phase 2Results posted
• Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)Active, not recruitingNCT06357988Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)Active, not recruitingNCT06357975Phase 2Results posted
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)Active, not recruitingNCT06351371Phase 2Results posted
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)Active, not recruitingNCT06308822Phase 2Results posted
• Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Active, not recruitingNCT06303167Phase 2Results posted
• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)Active, not recruitingNCT06136897Phase 2Results posted
• Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerActive, not recruitingNCT05996523Phase 2Results posted
• Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic SyndromesTerminatedNCT05918055Phase 1/2Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 DeficiencyActive, not recruitingNCT05907746Phase 2Results posted
• Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 TrialActive, not recruitingNCT05715281Phase 2Results posted
• Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)TerminatedNCT05554354Phase 2Results posted
• Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)Active, not recruitingNCT05490771Phase 2Results posted
• Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped WorkingActive, not recruitingNCT05432791Phase 2/3Results posted
• Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisActive, not recruitingNCT05413304Phase 1Results posted
• Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesCompletedNCT05371054Phase 1/2Results posted
• Olaparib in Subjects With Advanced Pancreatic Acinar Cell CarcinomaTerminatedNCT05286827Phase 2Results posted
• Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian CancerActive, not recruitingNCT05276973Phase 1Results posted
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemActive, not recruitingNCT05211336Phase 1Results posted
• Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the BodyTerminatedNCT05198843Phase 1/2Results posted
• Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisCompletedNCT05185947Phase 2Results posted
• BMS-986253 in Myelodysplastic SyndromesTerminatedNCT05148234Phase 1/2Results posted
• Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell MembraneActive, not recruitingNCT05146739Phase 1Results posted
• Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 TrialActive, not recruitingNCT05142241Phase 2Results posted
• Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsActive, not recruitingNCT05071209Phase 1/2Results posted
• T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial CancersTerminatedNCT05035407Phase 1Results posted
• Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).CompletedNCT05012098Phase 2Results posted
• 18F-DCFPyL PET/CT in Hepatocellular CarcinomaTerminatedNCT05009979Phase 2Results posted
• Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract CancerActive, not recruitingNCT04941287Phase 2Results posted
• Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial CancerTerminatedNCT04936230Phase 2Results posted
• Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell LymphomasTerminatedNCT04933617Phase 1Results posted
• Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)CompletedNCT04896073Phase 2Results posted
• Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain TumorCompletedNCT04852302Not applicableResults posted
• A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor TherapyCompletedNCT04847050Phase 2Results posted
• Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaTerminatedNCT04840615Phase 1Results posted
• Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia PatientsActive, not recruitingNCT04817241Phase 1/2Results posted
• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
• Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed OsteosarcomaTerminatedNCT04751383Phase 1Results posted
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 2Results posted
• Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaActive, not recruitingNCT04729959Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has SpreadCompletedNCT04631029Phase 1Results posted
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to BonesTerminatedNCT04616547Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsActive, not recruitingNCT04616534Phase 1Results posted
• Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedNCT04599634Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 1Results posted
• Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)CompletedNCT04574583Phase 1/2Results posted
• Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).TerminatedNCT04566133Phase 2Results posted
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingNCT04557956Phase 1/2Results posted
• Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to TreatmentTerminatedNCT04541017Phase 1/2Results posted
• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsTerminatedNCT04538378Phase 2Results posted
• Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation CarriersCompletedNCT04535414Phase 2Results posted
• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and IntestinesActive, not recruitingNCT04535401Phase 1Results posted
• Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate GlandCompletedNCT04530552Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerActive, not recruitingNCT04514497Phase 1Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial CarcinomaTerminatedNCT04501094Phase 2Results posted
• Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal CancersCompletedNCT04491955Phase 2Results posted
• E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical CancerTerminatedNCT04476251Early Phase 1Results posted

← National Cancer Institute (NCI) overview and focus areas